<DOC>
	<DOCNO>NCT01505075</DOCNO>
	<brief_summary>The purpose study determine safety efficacy short course radiotherapy ( 40Gy/5 fractions/29 day ) treatment high risk prostate cancer currently manage primary androgen deprivation therapy ( PADT ) .</brief_summary>
	<brief_title>Safety Efficacy Study Hypofractionated Radiotherapy Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description>Primary Endpoints : - Acute gastrointestinal ( GI ) genitourinary ( GU ) Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 toxicity Secondary Endpoints : - Late GI GU Radiation Therapy Oncology Group ( RTOG ) toxicities - Biochemical disease-free survival - Biopsy positive rate 3 year - Quality life use Expanded Prostate Cancer Index Composite ( EPIC ) questionnaire - Develop biobank DNA serum extract blood urine analyze develop new biomarkers prostate cancer progression susceptibility severe toxicity</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>informed consent obtain men &gt; 18 year histologically confirm prostate adenocarcinoma ( centrally review ) high risk prostate cancer , define least one : clinical stage T3 , gleason score 810 , PSA &gt; 20ng/mL prior pelvic radiotherapy anticoagulation medication ( unsafe discontinue gold seed insertion ) diagnosis bleed diathesis pelvic girth &gt; 40cm ( ensure visibility gold seed electronic portal imaging ) large prostate ( &gt; 90cm3 ) imaging severe low urinary tract symptom ( International Prostate Symptom Score &gt; 19 nocturia &gt; 3 ) No evidence castrate resistance ( define PSA &lt; 3ng/mL testosterone &lt; 0.7nmol/L ) . Patients could combine androgen blockade exclude start due PSA progression</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>prostatic neoplasm</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>hypofractionated</keyword>
	<keyword>high risk prostate cancer</keyword>
</DOC>